Revenue segments as reported by the company.

Life Sciences Solutions

Analytical Instruments

Specialty Diagnostics

Laboratory Products and Services

Eliminations

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Amortization of acquisition-related intangible assets

Research and development

Restructuring and other costs

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Thermo Fisher Scientific

Life Technologies was a biotech company founded in November 2008 through a US$6.7 billion merger of Invitrogen Corporation and Applied Biosystems Inc. The joint sales of the combined companies were about $3.5 billion; they had about 9,500 employees, and owned more than 3,600 licenses and patents.

Life Technologies

Thermo Fisher Scientific, Inc. engages in the provision of analytical instruments, equipment, reagents and consumables, software, and services for research, analysis, discovery, and diagnostics. It operates through the following segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services. The Life Sciences Solutions segment is composed of a portfolio of reagents, instruments, and consumables used in biological and medical research, discovery and production of new drugs and vaccines, as well as diagnosis of infection and disease. The Analytical Instruments segment offers instruments, consumables, software, and services that are used for a range of applications in the laboratory, on the production line, and in the field. The Specialty Diagnostics segment provides diagnostic test kits, reagents, culture media, instruments, and associated products used to increase the speed and accuracy of diagnoses. The Laboratory Products and Services segment is involved in providing everything needed for the laboratory, including a combination of self-manufactured and sourced products for customers in research, academic, government, industrial, and healthcare settings. The company was founded on October 11, 1960 and is headquartered in Waltham, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Thermo Fisher excels in 2022, eyes growth amid challenges

Thermo Fisher Scientific delivered exceptional 2022 results with strong Q4 performance and robust full-year revenue. Growth strategy and segment strengths position the company well for continued success in 2023.
Challenges such as normalization of growth, margin influences, and market dynamics require strategic management. Opportunities in high-growth markets and next-gen technologies offer avenues for further expansion and value creation.
Maintaining a focus on innovation, sustainability, and operational efficiency will be key to navigating challenges and capitalizing on growth opportunities in 2023.
Overall, Thermo Fisher Scientific's solid financial performance, strategic focus, and market positioning set a positive trajectory for continued success and value creation in the coming year.

Thermo Fisher excels in Q1 despite COVID challenges, eyes growth

Thermo Fisher Scientific's Q1 2023 showcased resilience amid challenges, driven by innovation and strategic initiatives. While facing short-term headwinds, the company remains well-positioned for long-term growth through market opportunities and operational strengths.

Thermo Fisher faces market challenges, focuses on cost management and acquisitions

Thermo Fisher Scientific navigated a challenging macroeconomic environment in Q2 2023, with varied performance across end markets. The company is focused on managing costs, driving productivity, and pursuing strategic acquisitions to enhance capabilities. Despite challenges, Thermo Fisher remains committed to ESG priorities and market outperformance.

Thermo Fisher reports solid Q3 earnings, eyes growth opportunities

Thermo Fisher Scientific's Q3 performance was solid, with revenue growth and strategic acquisitions driving market position strengthening.
While facing challenges like revenue impact in Q4 and customer caution, the company remains optimistic about industry outlook and growth opportunities.
The company's focus on innovation, ESG priorities, and operational efficiency positions it well for future growth and success.
Management's insights into 2024 outlook indicate a balanced approach to growth through strategic investments and operational improvements.

Thermo Fisher posts solid earnings, eyes growth amid market challenges

Thermo Fisher Scientific delivered strong financial performance in Q4 2023 and full-year 2023, driven by innovation and customer focus.
While facing challenges in certain segments and markets, the company remains optimistic about growth opportunities and market outpacing.
Strategic acquisitions, focus on sustainability, and operational excellence position Thermo Fisher for continued success in 2024 and beyond.
Guidance for 2024 indicates a focus on organic growth, stable segment margins, and a commitment to long-term market outperformance.

Thermo Fisher reports strong Q1 earnings, eyes growth opportunities

Thermo Fisher Scientific's Q1 2024 earnings call highlighted strong financial performance driven by a proven growth strategy and disciplined capital deployment. While facing challenges in certain end markets and regulatory uncertainties, the company remains optimistic about future growth opportunities. Key strengths include innovation, strategic partnerships, and a focus on corporate social responsibility.

Thermo Fisher excels in Q2, raises 2024 guidance amid market challenges

Thermo Fisher Scientific's Q2 performance reflects resilience and strategic focus amidst market challenges. The company's emphasis on innovation, operational efficiency, and customer relationships positions it well for sustained growth. With a positive outlook for 2024 and a commitment to long-term success, Thermo Fisher remains a strong player in the industry.

Thermo Fisher excels in Q3 earnings, eyes growth opportunities

Thermo Fisher Scientific's Q3 2024 earnings call showcased strong financial performance, strategic innovations, and growth opportunities.
While facing challenges in certain market segments, the company's focus on innovation, partnerships, and financial strength positions it well for future growth.
With raised EPS guidance and revenue expectations, Thermo Fisher is poised for continued success through market expansion and strategic initiatives.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CARLSBAD, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced the launch of the Thermo Scientific™ KingFisher™ Apex™ Dx, an automated nucleic acid purification instrument, and Applied Biosystems™ MagMAX™ Dx Viral/Pathogen NA Isolation Kit for the isolation and purification of viral and bacterial pathogens from respiratory biological specimens. Together these products provide laboratories with an in vitro diagnostic (IVD) and in vitro diag.

Thermo Fisher Scientific Introduces New Sample Preparation Solutions to Simplify and Automate Respiratory Diagnostic Testing

Atlas Energy Solutions Inc

AXA Equitable Holdings Inc

AESI, EQH and TMO have been added to the Zacks Rank #5 (Strong Sell) List on December 6, 2023.

New Strong Sell Stocks for December 6th

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced a 15-year virtual power purchasing agreement (VPPA) with international solar developer ib vogt. Thermo Fisher's 91-megawatt portion of the Serbal solar project will deliver approximately 192,000 megawatt hours of renewable electricity annually. Eurofins Scientific, a global leader in bioanalytical testing, collaborated in the aggregated deal for a 36-megawatt portion.

Thermo Fisher Scientific Establishes 2030 Renewable Electricity Goal and Solar Power Purchase Agreement with ib vogt

Thermo Fisher (TMO) announces a collaboration with Project HOPE to improve health outcomes by enabling expanded access to HIV testing and support services in Nigeria.

Thermo Fisher (TMO) Advances Health Equity via New Partnership

Thermo Fisher Scientific is facing temporary revenue headwinds due to reduced COVID-19-related sales and cautious customer spending. The company's organic revenues are expected to bottom in FY24 and see a reacceleration in growth from FY25 onwards which can help the stock re-rate. TMO's valuation is cheap compared to historical averages and peers, offering a good buying opportunity.

Thermo Fisher Scientific: A Good Buy Near The Bottom

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, and Project HOPE, a leading global health and humanitarian organization, today announced a new partnership to improve the wellbeing and treatment outcomes of adolescents and young persons living with HIV in Nigeria, the country with the second largest HIV epidemic worldwide. Nigeria currently accounts for nearly two million individuals living with HIV, contributing to approximately two-thirds of.

Thermo Fisher Scientific and Project HOPE Partner to Advance Health Equity Among HIV Positive Youth in Sub-Saharan Africa

Thermo Fisher's (TMO) in-depth knowledge of the life sciences sector will be combined with Flagship Pioneering to create revolutionary capabilities for the ecosystem.

Thermo Fisher (TMO) Extends Partnership With Flagship Pioneering

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”) announced today that it has priced an offering of $2.5 billion aggregate principal amount (the “Offering”) of the following notes: $1.0 billion aggregate principal amount of its 5.000% senior notes due 2026 (the “2026 notes”), at the issue price of 99.931% of their principal amount; $1.0 billion aggregate principal amount of its 5.000% senior notes due 2029 (the “2029 notes”), at the issue price of 99.7.

Thermo Fisher Scientific Prices Offering of USD-Denominated Senior Notes

WALTHAM, Mass. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and Flagship Pioneering, the bioplatform innovation company, today announced the formation of a strategic partnership to develop and commercially scale multiproduct platforms on an accelerated basis. Through this collaboration, Thermo Fisher and Flagship will work together to create new platform companies focusing on novel tools and capabilities that seek to power.

Thermo Fisher Scientific & Flagship Pioneering Expand Ongoing Strategic Partnership to Jointly Create New Platform Companies with First-in-Class Enabling Technologies for Life Sciences

Dollar General

Dick's Sporting Goods

After a downturn that ran from late summer to early fall, the stock market reversed higher on two pieces of good news. First, inflation seems to have stabilized.

3 High Dividend Growth Stocks to Buy in December 2023

Thermo Fisher (TMO) reported earnings 30 days ago. What's next for the stock?

Why Is Thermo Fisher (TMO) Up 10.8% Since Last Earnings Report?

Thermo Fisher Scientific (NYSE:TMO) Inc has announced a new $4 billion stock repurchase program, which represents about 2.3% of its market capitalization of $171.99 billion as of Monday's close.  The analytics, diagnostics and laboratory services company said the new buyback program, which has no expiration date, replaces the existing program that had $1 billion in repurchase authorization remaining.

Thermo Fisher Scientific reveals new $4B stock buyback program

Shares of Thermo Fisher Scientific Inc. TMO, -0.73% were little changed in premarket trading Tuesday, after the analytics, diagnostics and laboratory services company announced a new $4 billion stock repurchase program. The new program represents about 2.3% of the company's market capitalization of $171.99 billion as of Monday's close.

Thermo Fisher sets new $4 billion stock buyback program, about 2 weeks after shares hit a 3-year low

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today announced the opening of its Battery Customer Experience Center in Seoul, South Korea. The advanced facility will assist battery manufacturers in driving innovative solutions that support the United Nations Sustainable Development Goal of providing access to affordable, reliable, sustainable and modern energy for all people by 2030. It also will serve as a global hub for clean energy and batter.

Thermo Fisher Scientific Opens Customer Experience Center for Battery Manufacturing in Seoul

Olink Holding AB

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Olink Holding AB (publ) (NasdaqGS: OLK) to Thermo Fisher Scientific Inc. (NYSE: TMO). Under the terms of the proposed transaction, shareholders of Olink will receive $26.00 in cash for each common share of Olink that they own. KSF is seeking to determine whether this consideration and the process that led to i.

OLINK HOLDING INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Olink Holding AB - OLK

Thermo Fisher is seeing the collapse of its COVID-19 diagnostic business. It's also suffering from its customers tightening their purse strings.

Down 19% in 2023 So Far, Is Thermo Fisher Scientific Stock Still Worth Buying?

Abbott Labs

Thermo Fisher and Abbott are two of our key Healthcare holdings in our fund, and both are among our top 10 holdings overall. Abbott and Thermo Fisher focus on different industries which are Healthcare Equipment and Life Science Tools respectively. Both show strong revenue growth compared to the market average growth rate which indicates that both companies exhibit competitive advantages within their respective main markets.

Abbott Labs Vs. Thermo Fisher: Which Is The Better Healthcare Stock?

Thermo Fisher Scientific is a top wealth compounder with strong performance in the medical equipment industry. The company is well-positioned for long-term growth due to increasing healthcare demands and its role in research and development. Despite recent challenges, TMO has demonstrated resilience and adaptability, making it an attractive investment choice.

My Family Is Buying A Lot More Thermo Fisher Stock

WALTHAM, Mass. & UPPSALA, Sweden--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”), the world leader in serving science, and Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK), a leading provider of next-generation proteomics solutions, today announced that Thermo Fisher has commenced the previously announced tender offer (the “Offer") through a direct, wholly owned subsidiary of Thermo Fisher (the “Buyer”) to acquire all of the outstanding common shares and all of the.

Thermo Fisher Scientific Commences Tender Offer for All Outstanding Common Shares and ADSs of Olink

HILLSBORO, Ore.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, has introduced the Thermo Scientific™ Meridian™ EX System— an electron-beam-based failure analysis solution designed to enable precise fault localization on advanced semiconductor logic technologies. As semiconductor manufacturers adopt more complex architectures to deliver higher performing, energy efficient semiconductors, they are pushing the boundaries of existing failure analysis solutions. Whe.

Thermo Fisher Scientific Announces New Fault Localization Solution for the Analysis of Advanced Logic Semiconductors

Ally Financial

Texas Instruments

Ally Financial is a digital bank that offers a dividend yield above 5% at recent prices. Thermo Fisher Scientific's COVID-19 testing revenue has evaporated, but that won't stop the company from raising its dividend payout higher in the years ahead.

3 Beaten-Down Dividend Stocks You Could Regret Not Buying on the Dip

Thermo Fisher Scientific Inc. (NYSE:TMO ) Q3 2023 Earnings Call Transcript October 25, 2023 8:30 AM ET Company Participants Rafael Tejada - VP of IR Marc Casper - Chairman, President and CEO Stephen Williamson - SVP and CFO Conference Call Participants Jack Meehan - Nephron Research Dan Brennan - TD Cowen Derik de Bruin - Bank of America Rachel Vatnsdal - J.P. Morgan Puneet Souda - Leerink Partners Eve Burstein - Bernstein Operator Good morning, ladies and gentlemen, and welcome to the Thermo Fisher Scientific 2023 Third Quarter Conference Call.

Thermo Fisher Scientific Inc. (TMO) Q3 2023 Earnings Call Transcript

Automatic Data Processing

Boeing

The Dow is the sole major index in the green this morning, boosted by Microsoft's strong performance yesterday afternoon.

Q3 Earnings Mixed, Big Results Expected After-Hours

Shares of Thermo Fisher Scientific (TMO) slumped over 7% in early trading Wednesday after the maker of lab equipment and analytical instruments posted weaker-than-expected sales and cut its outlook for a second-straight quarter on slowing demand.

Thermo Fisher Cuts Its Outlook For Second-Straight Quarter Amid Weakening Market

Thermo Fisher's (TMO) PPI Business System and strong execution by its global team enabled the company to deliver strong financial performance for Q3.

News for Thermo Fisher Scientific Stock (TMO)